SPAS(SH:603168) Zhong Guo Zheng Quan Bao - Zhong Zheng Wang·2025-09-02 23:39Core Points - Zhejiang Shapuaisi Pharmaceutical Co., Ltd. has received the Drug Registration Certificate for Sulfate Terbutaline Nebulization Solution from the National Medical Products Administration [1][4] - The approved drug is indicated for alleviating bronchial asthma, chronic bronchitis, emphysema, and other pulmonary diseases associated with bronchospasm [2] - The total R&D investment for this drug has reached approximately 5.0111 million RMB [3] Drug Registration Details - Drug Name: Sulfate Terbutaline Nebulization Solution [1] - Dosage Form: Inhalation preparation [1] - Specification: 2ml: 5mg [1] - Registration Classification: Chemical drug category 4 [1] - Approval Number: National Drug Approval Code H20255228 [1] - License Holder: Zhejiang Shapuaisi Pharmaceutical Co., Ltd. [1] - Approval Conclusion: The drug meets the registration requirements as per the Drug Administration Law of the People's Republic of China [1] Impact on the Company - The approval of the Sulfate Terbutaline Nebulization Solution will enrich the company's product portfolio and optimize its product layout [4] - Future production and sales of the drug are subject to uncertainties influenced by pharmaceutical industry policies, bidding procurement, and market environment changes [4]